Madero L, Villa M, Benito A, Gonzalez M, Diaz M A
Department of Pediatric Hematology and Oncology, Hospital Niño Jesús, Autonomous University of Madrid, Spain.
Bone Marrow Transplant. 1998 Apr;21 Suppl 2:S8-10.
Autologous peripheral blood progenitor cell transplantation has become an accepted procedure to support high dose chemotherapy in adults and children with cancer. The use of hematopoietic growth factors alone for mobilization of PBSC avoids the potential side effects of myelotoxic regimens and is as effective in reconstituting hematopoiesis as other mobilization methods. Many problems associated with apheresis procedures arise when PBPCs are harvested in small children. Large-volume-leukapheresis using a continuous flow blood cell separator allows us the collection of peripheral blood stem cells in children, even in the small ones. The speed of hematological recovery highly correlates with the number of CD34+ infused cells. We consider that a CD34+ cell dose of 5.0 x 10(6)/kg may be sufficient to ensure a rapid neutrophil and platelet recovery in pediatric patients mobilized by G-CSF.
自体外周血祖细胞移植已成为支持癌症成人和儿童进行高剂量化疗的一种公认方法。单独使用造血生长因子来动员外周血干细胞可避免骨髓毒性方案的潜在副作用，并且在重建造血功能方面与其他动员方法一样有效。在幼儿采集外周血祖细胞时会出现许多与单采程序相关的问题。使用连续流动血细胞分离器进行大容量白细胞单采使我们能够在儿童甚至是幼儿中采集外周血干细胞。血液学恢复速度与输注的CD34+细胞数量高度相关。我们认为，对于通过粒细胞集落刺激因子动员的儿科患者，5.0×10(6)/kg的CD34+细胞剂量可能足以确保中性粒细胞和血小板快速恢复。
